SAN DIEGO--(BUSINESS WIRE)--Batu Biologics, an immuno-oncology company dedicated to the development of its tumor endothelium vaccine, ValloVax™, announced today the appointment of Francesco M. Marincola, MD, FACS, to its scientific advisory board. In this capacity, Marincola will assist with the clinical development of ValloVax.
Marincola is the inaugural chief research officer of the Sidra Medical and Research Center (Sidra) based in Doha, Qatar, where he is tasked with building a world class, cutting-edge research program. Sidra will focus on high-level clinical care for women and children, and its research arm is placing a strong emphasis on translational medicine and immuno-oncology. The Center recently established a comprehensive program to identify genetic markers and biologic mechanisms that correlate with a patient’s predisposition to various diseases.
Marincola will also leverage his experience as a tenured senior investigator at the National Institutes of Health (NIH) in Bethesda, Maryland. Additionally, he serves as president of the Society for Immunotherapy of Cancer (SITC), a leading member-driven organization specifically dedicated to professionals working in the field of cancer immunology and immunotherapy.
“We are honored to have such an esteemed immunotherapy leader espouse our company’s vision to change the standard of care for solid tumors. Our collaboration will strengthen our efforts toward developing the tumor endothelium targeting vaccine, ValloVax™, which we hope will provide significant clinical benefit for cancer patients,” said Samuel C. Wagner, president and CEO of Batu Biologics.
“I strongly believe that immunotherapy will one day become the standard of care across the world and a key methodology for treating aggressive diseases like cancer,” commented Marincola. “Since the FDA approval of checkpoint inhibitors by Merck and Bristol-Myers Squibb, the bar has been set high for new drugs looking to enter the market in terms of clinical benefit. Batu Biologics has a highly novel approach to treating cancer with some remarkable early stage data and is on track to become a strong competitor in the field of immunotherapy.”
Batu Biologics has filed an Investigational New Drug (IND) application with the FDA and is awaiting approval to initiate a Phase I study for ValloVax™ in patients with non-small cell lung cancer.
About Batu Biologics
Batu Biologics is an immuno-oncology company developing novel gene and cellular based therapies for the treatment of cancer. The Company has filed an IND application for its lead therapeutic, ValloVax™, a multivalent therapeutic vaccine for Non Small Cell Lung Cancer targeting several tumor-angiogenesis associated antigens. ValloVax™ has demonstrated strong inhibition of tumor growth in several histologically distinct tumor models, and the company is currently raising funds that will enable the completion of a Phase I clinical study. The company maintains research facilities at JLABS, located in the Torrey Pines-area biotech cluster of San Diego.